Glen Kwon

Credentials: Jens. T. Carstensen Chair Professor in Pharmaceutical Sciences
Vilas Distinguished Achievement Professor

Address:
BS 1986 Chemistry - University of Utah
PhD 1991 Pharmaceutics - University of Utah
Postdoc 1993 Bioengineering - Tokyo Women's Medical College

Glen S. Kwon is a globally recognized pharmaceutical scientist and educator. His pioneering research in drug delivery and nanomedicine has led to significant advances in cancer therapy and the treatment of fibrotic diseases. With a prolific publication record, major research funding, and active entrepreneurial involvement, he is a key figure in translating pharmaceutical innovations from the lab to clinical application.

Honors and Awards

2024 Dr. Glen Kwon is honored with a Vilas Distinguished Achievement Professorship, recognizing distinguished scholarship and standout efforts in teaching and service.
2019 Co-D Therapeutics, a Madison-based company co-founded by Glen Kwon, was selected by NCI’s Nanomedicine Characterization Laboratory (NCL) as one of the most promising cancer nanomedicine candidates into its Assay Cascade Characterization and Testing Program for evaluation of a novel paclitaxel prodrug nanomedicine
2018 American Association of Pharmaceutical Sciences (AAPS) Best Abstract Award
2018 Dr. Glen S. Kwon is a founding member of the Wisconsin Center for Nanobiosystems (WisCNano). The mission of WisCNano is to research novel nanotechnology that enable drug molecules to go to specific sites in the body.
2016 AAPS PharmSciTech Outstanding Manuscript Award
2015 Co-D Therapeutics, Inc., a pre-clinical stage pharmaceutical company developing agents for the treatment of cancer, was granted orphan designation for Triolimus for the treatment of Angiosarcoma. Triolimus technology was developed by Dr. Glen Kwon. He is co-founder and Chief Scientific Officer of Co-D.
2014 Highly Cited Researcher, Thomson Reuters, Pharmacology & Toxicology
2013–2016 Board of Scientific Advisors, Controlled Release Society
2013 Co-D Therapeutics, a Madison-based company co-founded by Glen Kwon, was selected by Bioforward, a state biotechnology association, as a winner in its 2013 Emerging Company Showcase
2012 Fellow of AAPS
2009 A mini-review published by Monica Adams, Afsaneh Lavasanifar, and Glen S. Kwon, entitled “Amphiphilic block copolymers for drug delivery,” is the fifth-most highly cited article in 2009 by the Journal of Pharmaceutical Sciences. It reached 1,155 citations in 2021.
2005–2009 Regular Member, NIH Gene and Drug Delivery Systems Study Section
2003 Dr. Glen S. Kwon is a Founding Faculty Advisor for the UW Student Chapter for AAPS
2003 CRS Young Investigator Research Achievement Award
2001 Editorial Board, Journal of Controlled Release
2000–2009 Scientific Advisor Board, Nanocarrier Inc.
1998 NIH FIRST Award
1998 American Association of Colleges of Pharmacy (AACP) Faculty New Investigator Award
1994 Jorge Heller Journal of Controlled Release/CRS Outstanding Paper Award
1991–1993 Japan Society for the Promotion of Science (JSPS) Postdoctoral Fellowship